| Literature DB >> 29963000 |
Laurent M Willems1, Nina Watermann2, Saskia Richter2, Lara Kay1, Anke M Hermsen1, Susanne Knake2, Felix Rosenow1,2, Adam Strzelczyk1,2.
Abstract
Introduction: This study was designed to evaluate risk factors and incidence of epilepsy-related injuries and accidents (ERIA) at an outpatient clinic of a German epilepsy center providing healthcare to a mixed urban and rural population of over one million inhabitants.Entities:
Keywords: accident; epilepsy; falls; laceration; seizure
Year: 2018 PMID: 29963000 PMCID: PMC6013746 DOI: 10.3389/fneur.2018.00414
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Epilepsy syndromes within the cohort.
| Focal epilepsy | 75.0(219) |
| TLE | 49.0(143) |
| FLE | 10.6(31) |
| Other lobes | 5.1(15) |
| Multilobar | 4.5(13) |
| Other/cryptogenic | 5.8(17) |
| Idiopathic generalized epilepsy | 19.5(57) |
| IGE with grand mal on awakening | 0.3(1) |
| JME (Janz syndrome) | 4.8(14) |
| Juvenile absence epilepsy | 1.7(5) |
| Other | 12.7(37) |
| Unclassified | 5.5(16) |
TLE, temporal lobe epilepsy; FLE, frontal lobe epilepsy; IGE, idiopathic generalized epilepsy; JME, juvenile myoclonic epilepsy.
Sociodemographic and clinical characteristics of the entire cohort and for patients with focal and idiopathic generalized epilepsies.
| Age in years | 40.8 ± 15.6 | 43.1 ± 15.5 | 31.4 ± 12.5 | <0.001 | |
| Range:18–86 | Range: 18–86 | Range: 18–63 | |||
| Disease duration in years | 14.2 ± 19.8 | 14.3 ± 14.1 | 14.7 ± 13.6 | 0.881 | |
| Range: 0.1–63 | Range: 0.1–63 | Range: 0.1–55 | |||
| Sex | |||||
| Male | 45.2 (132) | 46.1 (101) | 40.4 (23) | 0.121 | |
| Female | 54.9 (160) | 53.9 (118) | 59.7 (34) | ||
| Anticonvulsants | Mean no of AED | 1.6 (±0.8) | 1.7(±0.8) | 1.5 (±0.6) | |
| No AEDs | 1.7 (5) | 0.18 (4) | 0.3 (1) | 0.958 | |
| Monotherapy | 48.3 (141) | 45.7 (100) | 54.4 (31) | ||
| 2 AEDs | 34.6 (101) | 34.7 (76) | 38.6 (22) | ||
| ≥3 AEDs | 15.4 (45) | 17.8 (39) | 7.0 (4) | ||
| Seizures | % ( | % ( | % ( | ||
| Seizure freedom >1 year | 32.2 (94) | 29.2 (64) | 45.6 (26) | 0.019 | |
| Active epilepsy | 67.8 (198) | 70.8 (155) | 54.5 (31) | ||
Mean ± standard deviation.
p-value calculated using T-Test.
p-value calculated using chi2-test.
Male vs. female.
Prescription pattern of anticonvulsant drugs within the cohort.
| Levetiracetam | 53.1(155) |
| Lamotrigine | 35.6(104) |
| Valproate | 16.1(47) |
| Carbamazepine | 11.6(34) |
| Lacosamide | 11.6(34) |
| Zonisamide | 9.2(27) |
| Oxcarbazepine | 7.5(22) |
| Perampanel | 6.2(18) |
| Topiramate | 3.8(11) |
| Pregabalin | 2.4(7) |
| Gabapentin | 1.7(5) |
| Clonazepam | 1.0(3) |
| Primidone | 1.0(3) |
| Ethosuximide | 1.0(3) |
| Phenobarbital | 0.7(2) |
| Eslicarbazepine | 0.3(1) |
| Stiripentol | 0.3(1) |
| Methsuximide | 0.3(1) |
| Phenytoine | 0.3(1) |
| Piracetam | 0.3(1) |
| Percentage of “old” AEDs | 28.8% |
| Percentage of enzyme-inducing AEDs | 13.7% |
Enzyme-inducing AEDs: carbamazepine, phenobarbital, primidone, and phenytoin; “old” AEDs: valproate, carbamazepine, phenobarbital and phenytoine.
Overview of patients with epilepsy-related injuries and accidents (ERIA, n = 41).
| – | FE | 3 | 61–70 | x | x | x | x | x | |||||||||
| 0.1 | IGE | 1 | 11–20 | x | x | x | x | ||||||||||
| 0.1 | FE | 1 | 31–40 | x | x | x | x | x | x | ||||||||
| 0.1 | IGE | 1 | 21–30 | x | x | x | x | ||||||||||
| 1 | FE | 1 | 51–60 | x | x | x | x | ||||||||||
| 1 | FE | 1 | 51–60 | x | x | x | x | x | |||||||||
| 1 | FE | 2 | 51–60 | x | x | x | x | ||||||||||
| 1 | FE | 3 | 21–30 | x | x | x | x | x | |||||||||
| 1 | FE | 1 | 11–20 | x | x | x | x | x | |||||||||
| 2 | FE | 3 | 61–70 | x | x | x | x | x | x | ||||||||
| 2 | FE | 2 | 31–40 | x | x | x | x | x | x | ||||||||
| 4 | FE | 1 | 11–20 | x | x | x | x | x | x | ||||||||
| 5 | FE | 1 | 61–70 | x | x | x | x | x | x | ||||||||
| 5 | IGE | 1 | 11–20 | x | x | x | |||||||||||
| 6 | FE | 2 | 31–40 | x | x | x | x | x | |||||||||
| 7 | FE | 2 | 31–40 | x | x | x | x | x | |||||||||
| 7 | IGE | 2 | 41–50 | x | x | x | x | ||||||||||
| 7 | FE | 1 | 11–20 | x | x | x | x | x | |||||||||
| 7 | FE | 3 | 41–50 | x | x | x | x | x | |||||||||
| 8 | FE | 2 | 21–30 | x | x | x | x | ||||||||||
| 10 | IGE | 3 | 21–30 | x | x | x | x | x | x | x | |||||||
| 11 | FE | 3 | 21–30 | x | x | x | x | x | x | x | |||||||
| 11 | FE | 1 | 21–30 | x | x | x | |||||||||||
| 11 | FE | 3 | 31–40 | x | x | x | x | x | x | ||||||||
| 11 | FE | 3 | 21–30 | x | x | x | x | ||||||||||
| 13 | FE | 2 | 51–60 | x | x | x | x | x | x | ||||||||
| 13 | FE | 3 | 31–40 | x | x | x | x | x | x | ||||||||
| 13 | FE | 0 | 41–40 | x | x | x | x | x | x | ||||||||
| 18 | FE | 3 | 31–40 | x | x | x | x | x | |||||||||
| 18 | IGE | 1 | 21–30 | x | x | x | x | x | |||||||||
| 22 | FE | 3 | 41–50 | x | x | x | x | x | |||||||||
| 26 | FE | 1 | 31–40 | x | x | x | x | x | x | ||||||||
| 27 | FE | 3 | 41–50 | x | x | x | x | x | |||||||||
| 28 | FE | 3 | 41–50 | x | x | x | x | x | |||||||||
| 29 | IGE | 2 | 31–40 | x | x | x | x | x | x | x | |||||||
| 29 | FE | 2 | 41–50 | x | x | x | x | x | |||||||||
| 37 | FE | 3 | 41–50 | x | x | x | x | x | x | ||||||||
| 41 | FE | 3 | 51–60 | x | x | x | x | x | x | x | |||||||
| 48 | IGE | 4 | 41–50 | x | x | x | x | x | x | ||||||||
| 53 | FE | 1 | 51–60 | x | x | x | |||||||||||
| 55 | FE | 3 | 61–70 | x | x | x | x | x | |||||||||
AEDs, anticonvulsant drugs; SPS, simple partial seizures; CPS, complex partial seizures; sGTCS, secondary generalized tonic-clonic seizures; pGTCS; primary generalized tonic-clonic seizures; mild injuries: biting of lips and tongue, small scrapes, mild contusion, myogelosis, aching muscles.
Frequency and clinical characteristics of patients with epilepsy-related injuries and accidents (ntotal = 292, nERIA = 41).
| Age | ≥50years | 82(87.2) | 12(12.8) | 94 | 0.2310 | 0.631 | 0.688 |
| <50 years | 166(85.1) | 29(14.9) | 195 | ||||
| Duration of epilepsy | ≥10 years | 114(84.4) | 21(15.5) | 135 | 0.4000 | 0.527 | 0.688 |
| <10 years | 128(87.1) | 19(12.9) | 147 | ||||
| Sex | Male | 110(84.6) | 20(15.4) | 130 | 0.2784 | 0.598 | 0.688 |
| Female | 138(86.8) | 21(13.2) | 159 | ||||
| Focal epilepsy | 184(84.8) | 33(15.2) | 217 | 0.8103 | 0.368 | 0.688 | |
| IGE | 51(89.5) | 6(10.5) | 57 | ||||
| Yes | 16(84.2) | 3(15.8) | 19 | 0.0429 | 0.836 | 0.688 | |
| No | 232(85.9) | 38(14.1) | 270 | ||||
| Seizure free > 1 year | Yes | 91(96.8) | 3(3.2) | 94 | 13.8347 | <0.001 | 0.006 |
| No | 157(80.5) | 38(19.5) | 195 | ||||
| No GTCS > 1 year | Yes | 179(92.3) | 15(7.7) | 194 | 20.1980 | <0.001 | 0.006 |
| No | 69(72.6) | 26(27.4) | 95 | ||||
| Refractory epilepsy | Yes | 57(76.0) | 18(24.0) | 75 | 8.0117 | 0.005 | 0.02 |
| No | 191(89.3) | 23(10.7) | 214 | ||||
| Ictal falls | Yes | 169(82.4) | 36(17.6) | 205 | 6.2858 | 0.012 | 0.036 |
| No | 77(93.9) | 5(6.1) | 82 | ||||
| Ictal loss of consciousness | Yes | 198(83.5) | 39(16.5) | 237 | 5.2314 | 0.022 | 0.044 |
| No | 48(96.0) | 2(4.0) | 50 | ||||
| Inadequate peri-ictal behavior | Yes | 44(75.9) | 14(24.1) | 58 | 4.3352 | 0.017 | 0.036 |
| No | 202(88.2) | 27(11.8) | 229 | ||||
| Nocturnal seizures only | Yes | 6(75.0) | 2(25.0) | 8 | 0.8299 | 0.362 | 0.688 |
| No | 240(86.3) | 38(13.7) | 278 | ||||
Newly diagnosed epilepsy, new onset epilepsy with ≥ 2 seizures within the last 12 months.
According to ILAE guidelines, IGE, idiopathic generalized epilepsy; GTCS, generalized tonic clonic seizure.
Adjusted for multiple testing using Benjamini-Hochberg-Adjustment.
Changes in mood and quality of life due to epilepsy-related injuries and accidents (ntotal = 292, n = 41).
| BDI | Depression | 41 (75.9) | 13 (24.1) | 54 | 5.3325 | 0.021 | 0.021a |
| (Score ≥ 14) | |||||||
| No depression | 207 (88.1) | 28 (11.9) | 235 | ||||
| (Score < 14) | |||||||
| NDDI-E | Major depression | 34 (72.3) | 13 (27.7) | 47 | 9.7522 | 0.002 | 0.003a |
| (Score ≥ 13) | |||||||
| No major depression | 154 (90.1) | 17 (9.9) | 171 | ||||
| (Score < 13) | |||||||
| QOLIE-31 | Overall T (mean ±SD) | 48.1 ± 10.8 | 38.9 ± 9.0 | 49.2 ± 10.4 | <0.001 | 0.002a | |
| Range | 17–68 | 22–56 | 17–68 | ||||
| EQ5D | VAS (mean ± SD) | 66.7 ± 19.3 | 56.0 ±19.1 | 68.4 ± 18.7 | <0.001 | 0.002a | |
| Range | 10–100 | 10–90 | 20–100 | ||||
| LEAP | Total (mean ± SD) | 39.9 ± 10.8 | 39.2± 10.9 | 44.6 ± 9.3 | 0.007 | 0.008a | |
| Range | 19–64 | 19–64 | 26–63 | ||||
| ABNAS | Total (mean ± SD) | 24.0 ± 16.7 | 35.8 ±17.9 | 22.2 ± 15.7 | <0.001 | 0.002a | |
| Range | range 0–72 | range 1–72 | range 0–63 | ||||
NDDI-E, Neurological Disorders Depression Inventory for Epilepsy; BDI, Becks depression inventory; QOLIE31, Quality of Life in Epilepsy Inventory; ABNAS, A-B Neuropsychological Assessment Schedule; EQ5D, Euro Quality of Life; LEAP, Liverpool Adverse Events Profile; a adjusted for multiple testing using Benjamini-Hochberg-Adjustment.
Standardized assessment and management of variables associated with ERIA.
| Short-term: | Generalized tonic clonic seizures | Average risk for ERIA |
| Long-term: | ||
| Active epilepsy | Safe surrounding | |
| “ | Protective helmets |
ERIA epilepsy-related injuries and accidents.
Variables associated with ERIA proposed by other publications.
Variables associated with ERIA according to our cohort.